UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
??? ?
(2022)
??????????? Smoking and COVID-19
in ????????
Mojtahed A
(2019)
Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases.
in Abdominal radiology (New York)
Topless RK
(2021)
Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank.
in ACR open rheumatology
Cassidy S
(2018)
Accelerometer-derived physical activity in those with cardio-metabolic disease compared to healthy adults: a UK Biobank study of 52,556 participants.
in Acta diabetologica
He Y
(2022)
Shared exposure liability of type 2 diabetes and other chronic conditions in the UK Biobank.
in Acta diabetologica
Veronese N
(2021)
Neurological diseases and COVID-19: prospective analyses using the UK Biobank.
in Acta neurologica Belgica
Broce IJ
(2019)
Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease.
in Acta neuropathologica
Hodgson K
(2020)
Cannabis use, depression and self-harm: phenotypic and genetic relationships.
in Addiction (Abingdon, England)
Mo C
(2023)
Evaluating the causal effect of tobacco smoking on white matter brain aging: a two-sample Mendelian randomization analysis in UK Biobank.
in Addiction (Abingdon, England)
Dao C
(2021)
The impact of removing former drinkers from genome-wide association studies of AUDIT-C.
in Addiction (Abingdon, England)
Song Q
(2022)
Panoramic smoking burden and genetic susceptibility in relation to all-cause and cause-specific mortality: a prospective study in UK Biobank.
in Addiction (Abingdon, England)
Au Yeung SL
(2022)
Association of smoking, lung function and COPD in COVID-19 risk: a two-step Mendelian randomization study.
in Addiction (Abingdon, England)
Bøstrand SMK
(2022)
Associations between alcohol use and accelerated biological ageing.
in Addiction biology
Wills AG
(2019)
Phenotypic and genetic relationship between BMI and cigarette smoking in a sample of UK adults.
in Addictive behaviors
Liu S
(2023)
Gene Expression has Distinct Associations with Brain Structure and Function in Major Depressive Disorder.
in Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Guo X
(2022)
927 MENDELIAN RANDOMIZATION ANALYSIS SHOWS A CAUSAL EFFECT OF NOISE EXPOSURE ON ALZHEIMER'S DISEASE RISK
in Age and Ageing
Hurst C
(2022)
684 LONG-TERM CONDITIONS, MULTIMORBIDITY, LIFESTYLE FACTORS AND GRIP STRENGTH CHANGE OVER 9 YEARS IN 44,315 UK BIOBANK PARTICIPANTS
in Age and Ageing
Lai Z
(2022)
Is ambient air pollution associated with sarcopenia? Results from a nation-wide cross-sectional study.
in Age and ageing
Nusinovici S
(2022)
Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk.
in Age and ageing
Politis M
(2023)
1310 FRAILTY, LONELINESS AND SOCIAL ISOLATION IN THE UK BIOBANK COHORT
in Age and Ageing
Mourtzi N
(2023)
Genetically downregulated Interleukin-6 signalling is associated with a lower risk of frailty.
in Age and ageing
McElheron M
(2022)
177 GENOME-WIDE ASSOCIATION ANALYSIS OF THE FRAILTY PHENOTYPE IN UK BIOBANK HIGHLIGHTS CARDIOMETABOLIC AND AUTOIMMUNE SIGNATURES IN AGEING
in Age and Ageing
Chen L
(2023)
Physical frailty, adherence to ideal cardiovascular health and risk of cardiovascular disease: a prospective cohort study
in Age and Ageing
Kuo CL
(2020)
ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants.
in Aging
Le Goallec A
(2019)
Age-dependent co-dependency structure of biomarkers in the general population of the United States.
in Aging
Araldi E
(2023)
Lithium treatment extends human lifespan: findings from the UK Biobank.
in Aging
Pyrkov TV
(2018)
Quantitative characterization of biological age and frailty based on locomotor activity records.
in Aging
Ma Y
(2023)
Genetic modification effects of physical frailty on the morbidity of mental disorders in the UK Biobank.
in Aging & mental health
Atkins JL
(2021)
A genome-wide association study of the frailty index highlights brain pathways in ageing.
in Aging cell
Zhang WB
(2021)
The antagonistic pleiotropy of insulin-like growth factor 1.
in Aging cell
Kuo CL
(2021)
Genetic associations for two biological age measures point to distinct aging phenotypes.
in Aging cell
Raisi-Estabragh Z
(2021)
Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank.
in Aging clinical and experimental research
Matloff WJ
(2020)
Interaction effect of alcohol consumption and Alzheimer disease polygenic risk score on the brain cortical thickness of cognitively normal subjects.
in Alcohol (Fayetteville, N.Y.)
Aliev F
(2022)
Genes regulating levels of ?-3 long-chain polyunsaturated fatty acids are associated with alcohol use disorder and consumption, and broader externalizing behavior in humans.
in Alcoholism, clinical and experimental research
Whitfield JB
(2022)
All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank.
in Alcoholism, clinical and experimental research
Lai D
(2022)
Evaluating risk for alcohol use disorder: Polygenic risk scores and family history
in Alcoholism: Clinical and Experimental Research
Tran KT
(2018)
Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
in Alimentary pharmacology & therapeutics
Nguyen TNM
(2022)
Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design.
in Alimentary pharmacology & therapeutics
Chen J
(2023)
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
in Alimentary pharmacology & therapeutics
Fu T
(2022)
Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants.
in Alimentary pharmacology & therapeutics
Yuan S
(2023)
Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
in Alimentary pharmacology & therapeutics
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |